文献速递垂体与肾上腺疾病

库欣综合征的肾上腺靶向药物治疗

Adrenally Directed Medical Therapies for Cushing Syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本文综述了库欣综合征的肾上腺靶向药物治疗。这类药物通过抑制肾上腺类固醇生成酶发挥作用,包括酮康唑、美替拉酮、奥西洛司他、米托坦和依托咪酯等,适用于术后持续或复发高皮质醇血症或无法手术的患者,需 careful 滴定和监测以避免肾上腺功能减退。

要点

  • 肾上腺靶向药物抑制肾上腺类固醇生成酶,用于库欣综合征的药物治疗。
  • 常用药物包括酮康唑、美替拉酮、奥西洛司他、米托坦和依托咪酯。
  • 所有药物需仔细剂量滴定和患者监测,以确保安全有效并避免肾上腺功能减退。

核心结论

  • 肾上腺靶向药物在库欣综合征管理中具有重要作用,尤其适用于术后持续或复发高皮质醇血症或无法手术的患者。
  • 使用这些药物需要充分的患者指导和密切监测,以确保治疗目标并尽量减少不良反应。

研究设计与样本

  • 本文为综述,通过电子文献检索纳入关于库欣综合征肾上腺靶向药物的研究。

主要发现

  • 肾上腺靶向药物抑制肾上腺类固醇生成中的一个或多个酶。
  • 现有药物包括酮康唑、美替拉酮、奥西洛司他、米托坦和依托咪酯,另有其他药物在研究中。
  • 不同药物在作用机制、药效时程、安全性和耐受性、药物相互作用潜力及给药途径方面存在差异。
  • 所有药物均需仔细剂量滴定和患者监测,以确保安全有效并避免肾上腺功能减退。

临床怎么用

  • 对于库欣综合征术后持续或复发高皮质醇血症或无法手术的患者,可考虑肾上腺靶向药物治疗。
  • 使用肾上腺靶向药物时需进行剂量滴定和密切监测,以平衡疗效与安全性,避免肾上腺功能减退。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Endogenous Cushing syndrome (CS) is characterized by excess cortisol secretion, which is driven by tumorous secretion of corticotropin in the majority of patients. Untreated, CS results in substantial morbidity and mortality. Tumor-directed surgery is generally the first-line therapy for CS. However, hypercortisolism may persist or recur postoperatively; in other cases, the underlying tumor may not be resectable or its location may not be known. Yet other patients may be acutely ill and require stabilization before definitive surgery. In all these cases, additional interventions are needed, including adrenally directed medical therapies. EVIDENCE ACQUISITION: Electronic literature searches were performed to identify studies pertaining to adrenally acting agents used for CS. Data were abstracted and used to compile this review article. EVIDENCE SYNTHESIS: Adrenally directed medical therapies inhibit one or several enzymes involved in adrenal steroidogenesis. Several adrenally acting medical therapies for CS are currently available, including ketoconazole, metyrapone, osilodrostat, mitotane, and etomidate. Additional agents are under investigation. Drugs differ with regards to details of their mechanism of action, time course of pharmacologic effect, safety and tolerability, potential for drug-drug interactions, and route of administration. All agents require careful dose titration and patient monitoring to ensure safety and effectiveness, while avoiding hypoadrenalism. CONCLUSIONS: These medications have an important role in the management of CS, particularly among patients with persistent or recurrent hypercortisolism postoperatively or those who cannot undergo tumor-directed surgery. Use of these drugs mandates adequate patient instruction and close monitoring to ensure treatment goals are being met while untoward adverse effects are minimized.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tritos NA. Adrenally Directed Medical Therapies for Cushing Syndrome. J Clin Endocrinol Metab. 2021. PMID: 33118025. doi:10.1210/clinem/dgaa778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。